Theriva Biologics (TOVX) vs Exicure (XCUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Exicure is the larger company by market cap ($5.9 million vs $5.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TOVX | XCUR |
|---|---|---|
| Share price | $0.12 | $0.9001 |
| Market cap | $5.51M | $5.89M |
| 1-day change | -6.25% | -12.82% |
| YTD return | -42.86% | — |
| 1-year return | -45.45% | — |
| 5-year return | -99.86% | — |
| P/E ratio (TTM) | 0.10 | — |
| EPS (TTM) | $1.15 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-23.74M | $-4.95M |
| 52-week high | $0.49 | $9.48 |
| 52-week low | $0.12 | $0.777 |
| Distance from 52-week high | -75.51% | -90.51% |
| Analyst consensus | none | — |
| Avg. price target upside | +1983.33% | — |
| Average volume | 2.02M | 53.56K |
| Shares outstanding | 45.89M | 6.55M |
| Employees | 15 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Exicure
XCUR stock →Exicure, Inc. does not have significant operations.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
TOVX vs XCUR FAQ
Which is bigger, Theriva Biologics or Exicure?
Exicure (XCUR) is larger, with a market capitalization of $5.89M compared with $5.51M for Theriva Biologics (TOVX).
Are Theriva Biologics and Exicure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.